Navigation Links
YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS
Date:11/11/2009

d business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation. It is significantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in 23 countries. In more than 5,000 patients reported as having been treated with nimotuzumab worldwide to date, no Grade IV incidents of radiation dermatitis have been described, severe rash has not been observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been rare. Nimotuzumab is licensed to YM's majority-owned subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. YM is developing AeroLEF for the treatment of moderate to severe acute pain. The product is differentiated from other approaches using opioids because patients are able to individually control the analgesia required for their differing intensities of pain. AeroLEF met all endpoints in a randomized Phase II trial and is currently being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Biofeedback – When a behavioral ... selecting medication to best treat it can become a ... using electroencephalography (EEG) can help predict which medicine will ... of adverse drug events. , The article “Medication ... current issue of the journal Biofeedback offers evidence that ...
(Date:7/21/2014)... California (PRWEB) July 21, 2014 ... County Workforce Investment Board (WIB) and Las Positas ... to provide technical education and hands-on training for ... Engineering Technology Program at Las Positas is ... training needed for engineering technician careers, and establishes ...
(Date:7/21/2014)... Syracuse University,s College of Arts and Sciences has ... of stainless nanoparticles. , Mathew M. Maye, associate ... $360,000 grant from the National Science Foundation (NSF). ... stainless alloy nanostructures, the results of which may ... batteries. , Maye,s approach is novel, ...
(Date:7/21/2014)... New York , July 21, 2014 /PRNewswire/ ... research on Global & USA ... Size, Trends, and Forecasts ResearchMoz presents ... Cancer Biomaker Market   to 2018 (Identification, Technologies, Market ... Industry Trends, and Pipeline Analysis. GLOBAL ...
Breaking Biology Technology:Analyzing Brain Patterns with EEG Can Help Predict Effective Use of Medication 2Analyzing Brain Patterns with EEG Can Help Predict Effective Use of Medication 3Engineering Program Established for Veterans 2Engineering Program Established for Veterans 3Syracuse University chemist to use NSF grant to study materials chemistry, nanoscience 2Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 2Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 3Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 4Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 5Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 6
... May 24, 2011 Benefiting from recent investments in production ... just reported another record quarter. The leading developer of topical ... up 126 percent over Q1 of 2010. It was the ... year ago. "Although Q1 delivered a stellar ...
... 2011 Radius Health, Inc. ("Radius") today announced that ... third financing round, including $66 million in equity financing ... and Oxford Finance LLC to a $25 million multi-draw ... AG, Brookside Capital, Saints Capital, Nordic Bioscience ("Nordic"), and ...
... A protein isolated from beneficial bacteria found in yogurt ... option for inflammatory bowel disorders (IBD), suggests a study ... M.D., Ph.D. The study, published May 23 in ... the protein, called p40, was effective as an intervention ...
Cached Biology Technology:First-quarter 2011 Sales Reach $2.25M — 126% Growth Over Q1 of 2010 — for Biotech Developer Divine Skin 2First-quarter 2011 Sales Reach $2.25M — 126% Growth Over Q1 of 2010 — for Biotech Developer Divine Skin 3Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study 2Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study 3Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study 4Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study 5Protein from probiotic bacteria may alleviate inflammatory bowel disorders 2Protein from probiotic bacteria may alleviate inflammatory bowel disorders 3
(Date:7/22/2014)... box and you,re likely to find that the lunches and ... findings of a study conducted by researchers at the Friedman ... in the Department of Public Health and Community Medicine at ... online ahead of print in the Journal of the ... senior author Jeanne Goldberg, Ph.D., R.D., a professor at the ...
(Date:7/22/2014)... 22, 2014, Cleveland: A type of immune cell ... such as Alzheimer,s disease and multiple sclerosis (MS), ... injury (TBI) and may slow the progression of ... today in the online journal Nature Communications ... Trapp, PhD, Chair of the Department of Neurosciences ...
(Date:7/21/2014)... Middle East Respiratory Syndrome coronavirus (MERS-CoV) in the air ... virus. The work, published this week in mBio ... for Microbiology, indicates that further studies are needed to ... air. , MERS, a serious viral respiratory illness caused ... as of June 11, according to the World Health ...
Breaking Biology News(10 mins):Room for improvement in elementary school children's lunches and snacks from home 2Cleveland Clinic researchers discover neuroprotective role of immune cell 2Middle East Respiratory Syndrome coronavirus detected in the air of a Saudi Arabian camel barn 2
... complaint against British drug maker GlaxoSmithKline (GSK) over its ... proceed following an order late last week by South ... go forward. GSK has sought outright dismissal of the ... week giving the complainants, AIDS Healthcare Foundation (AHF) and ...
... apples might do a better job of keeping the ... analyzed eight popular varieties of the fruit. Red Delicious, ... greater wallop of disease-fighting antioxidants than other apples studied. ... Agriculture and Agri-Food Canada in Guelph, Ontario, also pinpointed ...
... of an anti-inflammatory drug eliminated all of the cancer-causing ... when several genetic brakes to cancer formation were missing ... Cancer Center. , The investigators, who presented their findings ... for Cancer Research, say that while the results do ...
Cached Biology News:South African Tribunal Asks For Damages Estimates in GSK AIDS Drug Case 2Red delicious, Northern Spy apples have most antioxidants, chemists find 2NSAID drug protects against intestinal tumors in mice, despite poor diet and gene losses 2NSAID drug protects against intestinal tumors in mice, despite poor diet and gene losses 3
... muscle cell specific protein, is reported to be ... as intestine, lung and uterus. It shares structural ... expression has been reported in most tissues that ... forms. It is also reported to be expressed ...
PC based system for superior chemifluorescent, chemiluminescent, fluorescent and colorimetric, microarray and microscope imaging and analysis....
Request Info...
... Round Well Plate Sterile ... wide range of 384-well ... high-throughput screening and research. ... assays and are suitable ...
Biology Products: